Payment overview · 2025
General Payments
$115.36
6 reported records · 6 companies
Healthcare provider profile · identity verified
Bryan Everett Steele, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALTON, IL · NPI 1053503045
Verified facts
What the public records show
CMS Open Payments records show Bryan Everett Steele, MD received $115.36 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.66 | 23.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.45 | 21.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.89 | 18.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.70 | 12.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.67 | 12.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.99 | 12.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.36 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| THIRD WAVE Normalized: third wave |
Device | Hologic Sales and Service, LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 88 |
| Famotidine | Famotidine | 505 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 392 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 387 | 84 |
| Lisinopril | Lisinopril | 387 | 95 |
| Montelukast Sodium | Montelukast Sodium | 382 | 57 |
| Metformin Hcl | Metformin Hcl | 352 | 90 |
| Gabapentin | Gabapentin | 314 | 60 |
| Potassium Chloride | Potassium Chloride | 294 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 273 | 66 |
| Furosemide | Furosemide | 267 | 56 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 266 | 65 |
| Trazodone Hcl | Trazodone Hcl | 234 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 65 |
| Losartan Potassium | Losartan Potassium | 230 | 60 |
| Sertraline Hcl | Sertraline Hcl | 218 | 37 |
| Omeprazole | Omeprazole | 193 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 49 |
| Glipizide | Glipizide | 164 | 41 |
| Oxybutynin Chloride | Oxybutynin Chloride | 143 | 26 |
| Lactulose | Lactulose | 135 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 131 | 38 |
| Alendronate Sodium | Alendronate Sodium | 129 | 22 |
| Buspirone Hcl | Buspirone Hcl | 128 | 20 |
| Tradjenta | Linagliptin | 123 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 118 | 31 |
| Warfarin Sodium | Warfarin Sodium | 118 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 26 |
| Risperidone | Risperidone | 114 | suppressed |
| Carvedilol | Carvedilol | 103 | 30 |
| Baclofen | Baclofen | 101 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 101 | 75 |
| Naproxen | Naproxen | 99 | 29 |
| Spironolactone | Spironolactone | 99 | 14 |
| Simvastatin | Simvastatin | 97 | 17 |
| Lamotrigine | Lamotrigine | 96 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 93 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 85 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 13 |
| Jardiance | Empagliflozin | 82 | 24 |
| Tramadol Hcl | Tramadol Hcl | 81 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 56 |
| Ibuprofen | Ibuprofen | 79 | 17 |
| Eliquis | Apixaban | 78 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 30 |
| Fluconazole | Fluconazole | 74 | 19 |
| Lovastatin | Lovastatin | 74 | 21 |
| Meloxicam | Meloxicam | 71 | 25 |
| Nystatin | Nystatin | 70 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 15 |
| Celecoxib | Celecoxib | 66 | 16 |
| Divalproex Sodium | Divalproex Sodium | 65 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 18 |
| Nifedipine Er | Nifedipine | 62 | 15 |
| Metformin Hcl Er | Metformin Hcl | 61 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 59 | suppressed |
| Dulera | Mometasone/Formoterol | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | suppressed |
| Lorazepam | Lorazepam | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Alprazolam | Alprazolam | 55 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 54 | suppressed |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 40 |
| Terazosin Hcl | Terazosin Hcl | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 49 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 45 | suppressed |
| Cephalexin | Cephalexin | 45 | 30 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 21 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Prednisone | Prednisone | 41 | 19 |
| Clotrimazole | Clotrimazole | 40 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Lacosamide | Lacosamide | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Phenytoin | Phenytoin | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 25 | 11 |
| Ozempic | Semaglutide | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Desmopressin Acetate | Desmopressin Acetate | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Levocarnitine | Levocarnitine | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Epinephrine | Epinephrine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.36 · 6 records | ABBVIE INC. | APTIMA, Cologuard Collection Kit, GVOKE HYPOPEN, MOUNJARO, NURTEC ODT, QULIPTA, THINPREP 2000 PROCESSOR, THIRD WAVE, UBRELVY, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error